News
NVCR
12.18
+1.06%
0.13
Results Of Novocure's METIS Phase 3 Clinical Trial For Patients With Brain Metastasis From Non-Small Cell Lung Cancer To Be Presented As Late-Breaking Abstract At ASCO 2024
The results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago. METIS was a randomized trial of stereotactic radiosurgery with or without Tumor Treating Fields therapy for patients with 1-10 brain metastase from NSCLC. The METIS data will be present on June 3 as a late-breaking abstract.
Benzinga · 6h ago
Medpace (MEDP) Beats Q1 Earnings Estimates
NASDAQ · 2d ago
Analysts Anticipate ESML Will Reach $45
NASDAQ · 2d ago
Weekly Report: what happened at NVCR last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at NVCR last week (0408-0412)?
Weekly Report · 04/15 09:22
Commit To Buy NovoCure At $7.50, Earn 15.3% Using Options
NASDAQ · 04/12 15:34
Buy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution
TipRanks · 04/11 01:07
Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler
Dow Jones · 04/10 13:05
Piper Sandler Reiterates Overweight on NovoCure, Raises Price Target to $28
Benzinga · 04/10 12:55
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
NovoCure Limited (NASDAQ:NVCR) has US$568.8m of debt. The company uses debt in its business to fund its operations. NovoCure had a loss before interest and tax in the last year of US$509m. Its balance sheet shows it does not have a heavy debt load. However, the company has a negative free cash flow and is at risk of losing money. We've found 2 warning signs for Novocure that you should be aware of.
Simply Wall St · 04/08 10:40
Weekly Report: what happened at NVCR last week (0401-0405)?
Weekly Report · 04/08 09:23
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
20 presentations on Novocure’s Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research Annual Meeting 2024 in San Diego. The presentations include new insights on how TTFields therapy can potentially enhance the immune system's ability to combat cancer cells. Presentations on pancreatic cancer will also be presented.
Barchart · 04/05 06:00
Novocure Is Maintained at Overweight by Wells Fargo
Dow Jones · 04/03 16:53
Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $42
Benzinga · 04/03 16:43
NovoCure (NVCR) Receives a Buy from Wells Fargo
TipRanks · 04/02 23:05
NVCR, SBNY and VITL are among after hour movers
On the Move NVCR, SBNY and VITL are among after hour movers. Zapata Computing and Vital Farms are among the gainers. Signature Bank loses 11% of its value in the last 12 hours. The market is down 1% in the past day.
Seeking Alpha · 04/01 21:08
Weekly Report: what happened at NVCR last week (0325-0329)?
Weekly Report · 04/01 09:23
NovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price Target
TipRanks · 03/29 07:06
Why Novocure Stock Is Jumping Today
Shares of Novocure jumped 6.3% on Thursday. The company announced results from a phase 3 study in treating patients with brain metastases from non-small cell lung cancer. However, the company says key secondary endpoints of the study were not achieved. The healthcare stock has plunged more than 70% in the last year.
The Motley Fool · 03/28 15:50
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/28 09:10
More
Webull provides a variety of real-time NVCR stock news. You can receive the latest news about Novocure through multiple platforms. This information may help you make smarter investment decisions.
About NVCR
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.